The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | CARTITUDE-1 results: CAR-T against BCMA in R/R MM
Deepu Madduri, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the Phase Ib results from the ongoing CARTITUDE-1 study with ciltacabtagene autoleucel (cilta-cel; formerly JNJ-4528, a CAR-T cell therapy containing two BCMA-targeting single-domain antibodies (NCT03548207). This CAR T-cell therapy delivered early and deep responses, including measurable residual disease (MRD) negativity, with a manageable safety profile in patients with relapsed and/or refractory multiple myeloma (MM). This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
